Gael Touya on China market
From AptarGroup CEO: Consumer is still there, but our numbers reflect inventory adjustments post-COVID · · CNBC Television
“Chinese brands are bringing in the market in China and supplying those as well. Asia is not too bad for us.”
On , Gael Touya, President of Aptar Pharma at APTARGROUP INC, spoke about China market during AptarGroup CEO: Consumer is still there, but our numbers reflect inventory adjustments post-COVID on CNBC Television.
About Gael Touya
Gael Touya, President of Aptar Pharma at Aptargroup, has been discussing the company's performance and market conditions in recent interviews. Touya stated that the company's numbers reflect inventory adjustments following the COVID-19 pandemic, noting that while consumer demand remains, growth rates in fragrance and other segments have slowed from pandemic-era highs. He described tariffs as "neutral" for AptarGroup, citing the company's philosophy of serving regions from within the region)Skip. Touya also noted that the Chinese market has not seen the vigorous rebound some expected, but that Chinese brands are supplying the market and Asia remains a positive region for the company. Touya highlighted strong demand in the pharmaceutical sector, particularly for nasal sprays, inhalers, and sinus rinses, and said the company has invested over $180 million in capacity for biologic drugs including GLP-1 drugs. He identified weakness in the U.S. food and personal care home care segments, attributing it to changing consumer patterns and retailers working down COVID inventories. Touya noted that labor force issues have abated)Skip, and that the company's business is 75% outside the U.S., with travel retail driving growth in beauty and high-end fragrances. He described China as an important market and said the company is not in geopolitically sensitive areas.